Latest Breaking News On - Oncology sales - Page 1 : comparemela.com

Median Technologies, a World Leading Oncology Clinical Trial Imaging Services Provider, Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company

Median Technologies, a World Leading Oncology Clinical Trial Imaging Services Provider, Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalNicolas danoArjun murthyCompany parisImaging labPharmaceutical companyMaster service agreementBecomes preferred vendorMedian technologiesEuronext growthOncology sales

Gilead posts quarterly loss, revenue rises 5%

(Reuters) -Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales. For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the recent charge as well as incremental expenses related to the CymaBay deal. Wall Street analysts currently project Gilead's 2024 earnings at $3.94 a share on revenue of $27.5 billion, according to LSEG data.

United statesDeena beasleyGilead sciencesCymabay therapeuticsReporting by deena beasleyBill berkrotCymabay therapeuticsOncology sales

AstraZeneca Stock Flirts With Breakout As Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

AstraZeneca Stock Flirts With Breakout As Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

United kingdomAndrew berensLeerink berensBrian abrahamsBristol myers squibbBristol myersRegeneron pharmaceuticalsLeerink partnersMyers squibbZeneca stockOncology salesWall streetDupixent missedKaruna therapeutics

Gilead posts quarterly loss on acquisition charge, revenue rises 5%

(Reuters) -Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales. For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the recent charge as well as incremental expenses related to the CymaBay deal. Wall Street analysts currently project Gilead's 2024 earnings at $3.94 a share on revenue of $27.5 billion, according to LSEG data.

United statesDeena beasleyeditingDeena beasleyMichael yeeDrug administrationGilead sciencesCymabay therapeuticsReporting by deena beasleyeditingBill berkrotCymabay therapeuticsOncology sales

Roche sees pick up in growth as it overcomes drop in COVID sales

LONDON/FRANKFURT (Reuters) -Roche forecast a pick up in sales growth this year as it overcomes a slump in demand for its COVID-19 products and a decline in sales of a trio of established cancer drugs abates. Sales in 2023 rose 1% to 58.7 billion Swiss francs ($68 billion), slightly below analysts' average estimate of closer to 60 billion francs, according to LSEG data. CEO Thomas Schinecker told reporters it was a "significant achievement" that the company increased sales despite the sharp drop in demand for its COVID therapy and diagnostics kits.

Ludwig burgerThomas schineckerMichael perryMark potterMaggie fickCarmot therapeuticsSwiss francsThomas schineckerOverseas salesSales growthOncology sales